AbNano™ Anti-T-Cell VHH Library

Introducing the AbNano™ Anti-T-cell VHH library, a first in-class immune-derived single domain antibody library designed specifically to overcome the complexities of t-cell surface protein targeting.

Leveraging advanced immunization strategies and error-prone PCR diversification, this unique platform contains nearly 1 billion unique VHH molecules to rapidly identify novel antibody candidates.

Request Quote

3D rendering of blue immune cells dividing, representing cellular targets in immunology and VHH discovery workflows.

Anti-T-Cell Library Technical Overview

The AbNano™ library begins with immunizing llamas using unstimulated human CD3+ T-cells, capturing a broad spectrum of native epitopes.

Initial sequencing revealed a diversity of approximately one million unique VHH sequences, which were subsequently expanded through serial error-prone PCR, achieving a final diversity nearing one billion unique protein-level VHH sequences.

Key Benefits & Applications:

High Diversity & High Affinity: With Nearly one billion diverse VHH molecules, AbNano™ enable rapid discovery of nanomolar-affinity binders.
Unique Targeting Strategies: Immune-driven diversity ensures relevance and specificity in antibody identification.
Versatile Platform: Ideal for bioprocess optimization, diagnostics, and early therapeutic discovery

Schematic workflow of immune-derived VHH library generation, including CD3+ T-cell immunization, PBMC isolation, RNA extraction, RT-PCR, error-prone PCR diversification, and phage display construction for anti-T-cell antibody discovery.

Thumbnail preview of scientific poster outlining the AbNano™ Anti-T-Cell VHH Library workflow, highlighting immune-derived diversity and antibody discovery strategy.

What Separates Natural Libraries from Synthetic?

Unlike synthetic libraries, AbNano™ VHH libraries deliver immune-driven diversity for more relevant antibody discovery. This modular workflow is adaptable for future antibody campaigns in immunology and immuno-oncology.

See how this approach can accelerate your research: Download Poster >

Validated Targets & Affinity Data

CD3ε: 34 unique clonotypes identified from 116 hits using ELISA screening.
CD8α/CD8β: 43 unique clonotypes identified from 58 hits.
Binding affinities range from high nanomolar to low micromolar, ensuring robust interaction profiles suitable for a wide range of research applications.

Side-by-side bar graphs showing ELISA screening results for anti-T-cell VHH library clones against CD3ε and CD8α/CD8β, illustrating diverse binding affinities across clonal VHH shockates.

Figures: Clonal crude VHH were prepared by osmotic shock and assayed against recombinant CD3ε or CD8α/CD8β on streptavidin-coated plates. The single-point binding was detected by HRP-anti-VHH conjugate and ABTS.

Streamline Your Discovery Timelines

Reduce late-stage attrition and streamline discovery timelines by starting your antibody campaigns with our naturally derived, validated VHH library. Whether you’re supporting a technical team or evaluating innovative solutions at a strategic level, the AbNano™ platform is engineered to deliver impactful results swiftly and reliably.

Choose the workflow that best suits your project’s requirements:

Solid-Phase Panning: Rapid, precise identification of VHH binders using recombinant protein targets adsorbed onto styrene plates.
Solution-Phase Panning: Enhanced flexibility with biotinylated targets captured via streptavidin beads, ideal for native-like binding conditions.

You Might Also Be Interested In:

[Webinar] VHH Discovery by Phage Display
[Poster] Identifying and characterizing VHH binders with the AbNano™ VHH Naïve Library
[Article] Beyond mAbs: The Unrealized Potential of VHH Antibodies
[Service] Custom VHH Antibody Discovery Solutions